



INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 8th November, 2023

To,
General Manager,
Corporate Relationship,
BSE Limited, P J Tower,
Dalal Street,
Mumbai — 400 001

Sub: Outcome of Board Meeting held on Wednesday, November 8, 2023, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements)

Regulations, 2015.

Scrip Code: 541304

Ref: Indo Us Bio Tech Limited

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 8th November, 2023 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter/half year ended 30th September, 2023 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 05.30 P.M. and concluded at 06:00 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY
DIVYANGBHAI
JOSHI

Digitally signed by DIMPY
DIVYANGBHAI JOSHI
Date: 2023.11.08 18:01:50
+05'30'

Ms. Dimpy Joshi

Company Secretary & Compliance officer





INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited							
Statement of standalone unaudited financial results for the quarter ended on 30th September 2023							
PARTICULARS	Quarter Ended			Half year ended		Year ended 31-03-2023 (Audited)	
	30-09-2023 (Unaudited)	30-06-2023 (Unaudited)	30-09-2022 (Unaudited)	30-09-2023 (Unaudited)	30-09-2022 (Unaudited)		
I	Income						
	Revenue from operations	1,581.37	1,914.26	1,374.93	3,495.63	2,813.24	6,174.48
	Other income	0.31	2.86	(0.00)	3.16	0.03	2.08
	Total income from operations	1,581.68	1,917.12	1,374.92	3,498.80	2,813.27	6,176.56
II	Expenses						
	Purchases	354.09	107.61	56.33	461.70	307.04	526.78
	Production Expenses	1,216.76	775.10	795.64	1,991.86	1,498.48	4,297.17
	Change in Inventories	(577.95)	550.67	161.49	(27.29)	268.39	(312.39)
	Employee benefit expenses	35.65	31.76	32.70	67.42	67.04	152.50
	Finance costs	40.92	37.21	22.10	78.12	50.56	118.43
	Depreciation and amortization expenses	21.32	20.05	16.60	41.37	32.75	82.59
	Other expenses	293.51	149.99	130.20	443.49	249.30	572.78
	Total expenses	1,384.29	1,672.39	1,215.05	3,056.67	2,473.57	5,437.87
III	Profit/(Loss) before exceptional items and tax	197.39	244.73	159.87	442.12	339.70	738.68
IV	Exceptional items- Prior Period Items	-	-	-	-	-	-
V	Profit/(Loss) before tax	197.39	244.73	159.87	442.12	339.70	738.68
VI	Tax expenses						
	a) Current tax	9.38	11.62	30.00	21.00	30.00	33.93
	b) Income tax prior year	25.38	-	-	25.38	-	(2.41)
	b) Deferred tax	(4.28)	(4.22)	-	(8.50)	-	(16.88)
	Total tax expenses	30.47	7.41	30.00	37.88	30.00	14.65
VII	Net Profit/(Loss) for the period/year	166.92	237.32	129.87	404.24	309.70	724.04
VIII	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss:	-	-	-	-	-	-
	i) Remeasurement of post employment obligations	-	-	-	-	-	-
	ii) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income	-	-	-	-	-	-
IX	Total comprehensive income for the period/year (VII+VIII)	166.92	237.32	129.87	404.24	309.70	724.04
X	Paid-up equity share capital (face value of Rs. 10 per share)	2,005.20	1,002.60	1,002.60	2,005.20	1,002.60	1,002.60
XI	Other equity (excluding revaluation reserve)	3,848.62	4,684.30	4,031.62	3,848.62	4,031.62	4,446.98
XII	EPS in Rs. (Face Value of Rs. 10/- each)*						
	- Basic	0.83	1.18	0.65	2.02	1.54	3.61
	- Diluted	0.83	1.18	0.65	2.02	1.54	3.61
	*not annualised						



Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 001
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta -Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • **Web :** www.indousagriseeds.com





INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Notes

- (1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8th November 2023 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) The company has issued bonus share at the ratio 1:1 as on 01st September, 2023.
- (4) The figures have been regrouped/rearranged wherever necessary.

For, **INDO US BIO-TECH LIMITED**


DIRECTOR

Mr. Jagdish Ajudia
Managing Director
(DIN: 01745951)



**Gautam
Maheshchandra
Nandawat**

Digitally signed
by Gautam
Maheshchandra
Nandawat
Date: 2023.11.08
17:17:58 +05'30'

Place: Ahmedabad
Date: 08th November 2023,

Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • **Web :** www.indousagriseeds.com





INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Disclosure of Standalone Assets and Liabilities (Balance Sheet) as per Regulation 33 of the SEBI (Listing Obligations and Disclosures) Regulations, 2015 for the half year ended 30th September 2023

Standalone Assets and Liabilities (Balance Sheet) as at 30th September, 2023

	Amount In ₹ in Lakhs 30-Sep-23	Amount In ₹ in Lakhs 31-Mar-23
ASSETS		
Non-current assets		
(a) Property, Plant & Equipments/Tangible assets	703.88	736.77
Intangible assets	-	-
Capital work-in-progress	-	-
Intangible assets under development	339.52	136.71
(b) Other Financial Assets	-	-
(c) Deferred tax assets (Net)	-	-
(d) Other Non-current Assets	46.96	58.46
	18.31	23.63
Current assets	<u>1,124.68</u>	<u>955.58</u>
(a) Inventories	-	-
(b) Financial Assets	2,616.93	2,691.33
(i) Investments	-	-
(ii) Trade receivables	0	0
(iii) Cash and cash equivalents	3,328.74	2,474.22
(c) (iv) Others	26.14	18.95
(d) Current Tax Assets (net)	732.82	804.82
(e) Other Current Assets	-	-
Total	<u>6,704.63</u>	<u>5,990.94</u>
	<u>7,829.30</u>	<u>6,946.53</u>
EQUITY AND LIABILITIES		
Shareholders' funds		
(a) Share capital	-	-
(b) Other Equity	2,005.29	1,002.60
Share application money pending allotment	<u>3,791.76</u>	<u>4,446.98</u>
I) Non-Current Liabilities	<u>5,756.96</u>	<u>5,449.58</u>
(a) Financial Liabilities	-	-
(i) Borrowings	-	-
(b) Provisions	-	-
(c) Deferred tax liability (net)	334.81	170.47
(d) Other Non-current liabilities	-	-
II) Current liabilities	4.27	4.27
(a) Financial Liabilities	92.85	92.90
(i) Borrowings	431.93	267.64
(ii) Trade payables	-	-
(b) Other current liabilities	-	-
(c) Short-term provisions	1,160.88	989.44
(d) Current Tax Liabilities (Net)	415.34	139.64
Total	<u>18.71</u>	<u>90.12</u>
	<u>0.38</u>	<u>0.38</u>
	<u>45.10</u>	<u>9.72</u>
	<u>1,640.41</u>	<u>1,640.41</u>
	<u>7,829.30</u>	<u>6,946.53</u>

Note: Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013.

Gautam Maheshchandra Nandawat
Digitally signed by Gautam Maheshchandra Nandawat
Date: 2023.11.08 17:17:32 +0530



For **INDO US BIO-TECH LIMITED**

Regd. Office :
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

Jagdish D Ajaliya
Managing Director
For **INDO US BIO-TECH LIMITED**



INDO US BIO-TECH LIMITED
Director
IGNITION HOUSE R & D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • **Web :** www.indousagriseeds.com



INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited

Disclosure of Standalone Cash Flow Statement as per Regulation 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2023

Standalone Cash Flow Statement for the Half Year ended on 30th September 2023

	Amount in ₹ in Lakhs 30- Sep-2023		Amount in ₹ in Lakhs 31- Mar-2023	
	Unaudited	Audited	Unaudited	Audited
Cash flow from operating activities:				
Net profit before tax as per statement of profit and loss	340.43	738.68		
Adjusted for:				
Preliminary expenses	0.00	0.68		
Provision for gratuity	41.37	82.59		
Depreciation & amortization	-	-		
Interest income on loans & advances given	78.12	118.43		
Interest & finance costs	459.93	940.39		
Operating cash flow before working capital changes				
Adjusted for:				
(Increase)/ decrease in inventories	74.40	(355.62)		
(Increase)/ decrease in trade receivables	(854.52)	(420.09)		
(Increase)/ decrease in other current assets	1.62	3.07		
(Increase)/ decrease in other non current assets	5.32	(0.70)		
Increase/ (decrease) in other non current liabilities	(0.06)	(12.55)		
Increase/ (decrease) in trade payables	275.70	(76.08)		
Increase/ (decrease) in other current liabilities	(71.41)	5.65		
Cash generated from / (used in) operations	(109.01)	84.06		
Income taxes paid	(6.17)	(31.49)		
Net cash generated from/ (used in) operating activities	[A] (115.18)	52.57		
Cash flow from investing activities:				
Purchase of fixed assets and capital advance paid	(207.29)	(182.26)		
Subsidy Received against Fixed Assets	-	12.50		
Proceeds from sale of shares in Subsidiary Company	-	0.99		
Increase/ decrease in short term loans and advances	72.00	(498.62)		
Interest income on loans & advances given	-	-		
Net cash flow from/(used) in investing activities	[B] (135.29)	(667.39)		
Cash flow from financing activities:				
Proceeds from issue of equity shares / Addition in Capital	(0.00)	837.64		
Dividend Paid	-	-		
Proceeds from long term borrowing (net)	164.34	(169.63)		
Proceeds from short term borrowing (net)	171.44	78.84		
Interest & finance costs	(78.12)	(117.89)		
Net cash flow from/(used in) financing activities	[C] 257.65	628.95		
Net increase/(decrease) in cash & cash equivalents	[A+B+C] 7.18	14.12		
Cash & cash equivalents as at beginning of the year	18.95	4.83		
Cash & cash equivalents as at end of the year	26.14	18.95		

Gautam Maheshchandra Nandawat
Date: 2023.11.08
17:16:23 +05'30'

Ahemdabad



Regd. Office:
309, Shanti Mall, Satadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

For, INDO US BIO-TECH LIMITED

Jagdish D Ajnliya
Managing Director
DIN: 0174991

Jagdish D Ajnliya
DIRECTOR

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousexim@gmail.com • Web : www.indousagriseeds.com





LIMITED REVIEW REPORT

To,
The Board of Directors
Indo US Bio-Tech Limited
Ahmedabad

1. We have reviewed the accompanying statement of unaudited financial results of **Indo US Bio-Tech Limited** for the half year ended 30th September 2023, Assets and Liability Statement and Cash Flow Statement ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No CIR/CFD/CMD1/44/2019 dated 29th March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of Listing Regulations, to the extent applicable.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W

Gautam Maheshchandra Nandawat
Digitally signed by
Gautam Maheshchandra
Nandawat
Date: 2023.11.08
16:39:03 +05:30



Gautam Nandawat
Partner,
M No: 032742
UDIN: 23032742BGSSTT5963

Place: Chhatrapati Sambhajinagar
Date: 8th November 2023